Gyermekkori daganatok: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• ABL1 2
• NF1 12
• HER2 25
• PI3K 5
• AKT 1
• PD-L1 13
• CDK4/6 7
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• PSMA 20
• KMT2A 12
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• CD38 5
• EZH2 0
• RAS 1
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

61+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

  NCT04260009· Takeda· Frissítve: 2020. márc. 5.

  “Business reason unrelated to product safety”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

  NCT04774718· Hoffmann-La Roche· Forrás

• Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma

  NCT07916389· St. Jude Children's Research Hospital· Forrás

• A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

  NCT03194893· Hoffmann-La Roche· Forrás

• A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  NCT04094610· Turning Point Therapeutics, Inc.· Forrás

• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  NCT02650401· Hoffmann-La Roche· Forrás

• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

  NCT02584933· Novartis Pharmaceuticals· Forrás

• Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2) - NIVO ALCL

  2024-516807-17-00· Institut Gustave Roussy· Forrás

• DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

  NCT05722886· Cancer Research UK· Forrás

• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  NCT03093116· Turning Point Therapeutics, Inc.· Forrás

• Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

  NCT04925609· Princess Maxima Center for Pediatric Oncology· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 31
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 87
• Immunohistochemistry 197
• Liquid Biopsy 25
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 520
• Machine Learning 67
• Deep Learning 25
• Cohort Studies 328
• Genome-Wide Association Study 22

• A noninvasive risk stratification prediction model for neuroblastoma through integration of multidimensional clinical indicators.

  Eur J Pediatr, 2026. nov.

• Unveiling Cerebrospinal Fluid Protein Biomarkers in Pediatric Acute Lymphoblastic Leukemia Using a Proximity Extension Assay.

  J Proteome Res, 2026. nov.

• Biomineralized SERS Nanotags Encode Biomolecular Identity into Machine Learning-Resolvable Fingerprints.

  ACS Appl Mater Interfaces, 2026. szept.

• Radiomics and machine learning for differentiating pediatric intramedullary spinal tumors: a pilot study.

  Eur Radiol Exp, 2026. szept.

• Artificial Intelligence for Diagnosis, Risk Stratification, and Prognosis of Neuroblastoma - A Systematic Review and Meta-Analysis.

  Curr Oncol Rep, 2026. szept.

• Development and Validation of an Interpretable Machine Learning Model for Predicting Early Pulmonary Metastasis Risk in Osteosarcoma.

  Cancer Med, 2026. szept.

• Evaluating the impact of segmentation strategies on radiomic feature stability for paediatric brain tumour diagnosis using diffusion weighted imaging.

  PLoS One, 2026. aug.

• Harmonizing Multi-Institutional Clinical Documentation Using Natural Language Processing in Neurofibromatosis Type 1.

  Neurol Clin Pract, 2026. aug.

• A Machine Learning Pipeline to Analyze Global Sentiment and Factors Influencing Retinoblastoma Treatment Hesitancy: Observational Infodemiology Study.

  J Med Internet Res, 2026. aug.

• Multiparametric MRI radiomics for noninvasive risk stratification of pediatric neuroblastoma: a pilot study.

  Sci Rep, 2026. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.